Anders Fuglsang, PhD
Dr Anders Fuglsang graduated in 1998 from the Royal Danish School of Pharmacy, Copenhagen, spending part of his studies at Leiden University, in the Netherlands. He was awarded his PhD in 2002 specialising in cardiovascular pharmacology. Following work as an Assistant Professor, he worked as a consultant for a number of Originator Pharmaceutical companies at a brand optimisation company in Copenhagen. In 2005, he joined the Norwegian Medicines Agency as a Clinical Assessor and became Expert Advisor to the WHO and member of the Efficacy Working. Party at the EM(E)A. Dr Anders Fuglsang was Chair of the sub-group for Orally Inhaled Products which published the 2009 guideline on Therapeutic Equivalence for inhalation products (still in force), and was also a member of the PK-subgroup. Other duties included provision of Expert Scientific Advice, GLP/GCP-inspection and -training, and responsibility for Assessor Training for Inhaled Products at the EM(E)A. Through 2009 to September 2010, he was Clinical and Regulatory Strategy Manager at a world leading generic company. Dr Anders Fuglsang has now established his own pharmaceutical consultancy, Fuglsang Pharma. Present and former clients include the World Health Organization (WHO), regulatory agencies, United States Pharmacopeial Convention (USP) and private companies. Dr Anders Fuglsang has authored approximately 45 papers in the fields of Pharmacokinetics, Generics, Genetics and Pharmacology, and has served as reviewer for some 15+ international journals including Science, Trends in Genetics and Drug Discovery Today.